Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus GVS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus GVS.
GENTAK vs GVS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
GVS is not a recognized drug. No mechanism of action available.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic